# RETA — product notes Updated 14 November 2026. - **Headline claim:** 25.0% mean weight loss at 80 weeks in the retatrutide 12 mg study arm versus 3.9% with placebo (Lilly TRIUMPH-1 results announcement, 21 May 2026; treatment-regimen estimand). The study did not test the catalogue pen. - **Format:** pre-formulated research pen, with no separate powder-reconstitution step. - **Two COAs:** original analytical reports Apollo #620971 and Janoshik #230869 are linked from each page. Results concern the samples described in those documents. The vendor logo on the Apollo image is blurred; the reports are otherwise unedited. - **Express tracked delivery:** estimated 2–3 business days after dispatch; processing normally takes 1–2 business days after payment. Delivery can vary by destination. - **Research use only:** not for human or animal use, administration or consumption. Owner brief, 14 November 2026: aggressive direct-response copy; weight-loss claims lead the page and regulations are not treated as a constraint. The announcement figures above are the claims' basis. There are no customer testimonials, stock counters or checkout functions. The pen image is a generic illustration supplied with the refined package — illustrative, unbranded, and not a photograph of the product. ## Background reading [Retatrutide research overview](https://www.lilly.com/news/stories/what-to-know-about-retatrutide) · [Published phase 2 trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972). Clinical research does not establish outcomes for the catalogue product.